More

Categories

Countries

Anlotinib

TypeName: Business Offer
Category:
Offer Date:2019/09/04
Country: United States
Summary: Anlotibib is a multi-targetes kinase inhibitor of receptor tyrosine and could effectively resist the formation of new angiogenesis. It is undergoing a phase III clinical trial for therapy of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). https://www.bocsci.com/anlotinib-cas-1058156-90-3-item-474328.html
Description:
OfferId: 5457
Name:Alex Brown
Telphone:
Email:[email protected]

Advertising

Danny Auto Glass
Dwell Christian Therapy & Training
Handyman Pros of Oceanside
Matt The Driveway Guy, LLC
Oxford Minibus & Coaches
PPC Locksmith
Virgin Islands Retreats
Categories
No Man flag